Sign in
4

Changes in Ownership

Inhibikase Therapeutics, Inc. Filed Acc 0000950170-25-007746

Options or other derivatives

  • Chief Financial Officer acquired 95,834 shares (grant or award)
  • Chief Financial Officer returned 95,834 shares (to the company)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
Lees-Rolfe Garth Chief Financial Officer 2025-01-21 Returned to the company · Stock Option (Right to Buy) −5,834 0 D
Lees-Rolfe Garth Chief Financial Officer 2025-01-21 Grant or award · Stock Option (Right to Buy) +5,834 5,834 D
Lees-Rolfe Garth Chief Financial Officer 2025-01-21 Returned to the company · Stock Option (Right to Buy) −90,000 0 D
Lees-Rolfe Garth Chief Financial Officer 2025-01-21 Grant or award · Stock Option (Right to Buy) +90,000 90,000 D
Loading xslF345X05/ownership.xml…